Skip to main content

Advertisement

SpringerLink
Log in

Diabetes

When insulin isn’t enough: targeting glucagon in type 1 diabetes

  • News & Views
  • Published:

From Nature Medicine

View current issue Submit your manuscript

A phase 2 study fails to meet its primary endpoint, but the treatment — a glucagon receptor antagonist — shows clinically relevant improvements in glycemic control, warranting further investigation as a potential adjunct to insulin.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1: Meal-related glycemic excursions despite insulin therapy.

References

  1. Foster, N. C. et al. Diabetes Technol Ther. 21, 66–72 (2019).

    Article  CAS  Google Scholar 

  2. Pettus, J. et al. Nat. Med. https://doi.org/10.1038/s41591-022-02011-x (2022).

    Article  PubMed  Google Scholar 

  3. Unger, R. H. & Orci, L. Proc. Natl Acad. Sci. USA 107, 16009–16012 (2010).

    Article  CAS  Google Scholar 

  4. Brown, R. J., Sinaii, N. & Rother, K. I. Diabetes Care 31, 1403–1404 (2008).

    Article  CAS  Google Scholar 

  5. Sherr, J. et al. Diabetes Care 37, 1741–1744 (2014).

    Article  Google Scholar 

  6. Gerich, J. E. et al. Science 182, 171–173 (1973).

    Article  CAS  Google Scholar 

  7. Pearson, M. J., Unger, R. H. & Holland, W. L. Diabetes Care 39, 1075–1077 (2016).

    Article  Google Scholar 

  8. Kelly, R. P. et al. Diabetes Obes. Metab. 17, 414–422 (2015).

    Article  CAS  Google Scholar 

  9. Pettus, J. et al. Diabetes Obes. Metab. 20, 1302–1305 (2018).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Yale School of Medicine, Department of Pediatrics, New Haven, CT, USA

    Michelle Van Name & Jennifer Sherr

Authors
  1. Michelle Van Name
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jennifer Sherr
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jennifer Sherr.

Ethics declarations

Competing interests

M.A.V. reports research support from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) and Provention Bio. J.L.S. reports research support from the Juvenile Diabetes Research Foundation, Insulet, Medtronic and NIDDK; has served on advisory boards for Bigfoot Biomedical, Cecelia Health, Insulet, Medtronic Diabetes, StartUp Health Diabetes Moonshot and Vertex; and has done consulting work for Cecelia Health, Eli Lilly, Insulet, Medtronic and Zealand.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Van Name, M., Sherr, J. When insulin isn’t enough: targeting glucagon in type 1 diabetes. Nat Med 28, 2007–2008 (2022). https://doi.org/10.1038/s41591-022-02019-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41591-022-02019-3

  • Springer Nature America, Inc.

Search

Navigation